Sobi nears record high on Pareto buy rating, upside seen

Swedish biopharma Sobi approaches record high after Pareto Securities initiates/upgrades with a buy recommendation, citing overly cautious guidance. The move reflects analyst optimism on earnings upside, but the stock's valuation may already price in expectations.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works